Oman's OIA bets on Neuralink: sovereign capital inside the human skull.

Five patients with severe quadriplegia. A chip called "Telepathy." The ability to move a cursor on screen using thought alone — no physical movement [2]. That is what Neuralink has achieved so far. That is what the Oman Investment Authority backed on May 6, 2026 [1].

The return will not be measured next quarter. The company remains private, with no IPO on the near horizon. But a sovereign fund does not buy a share — it buys a seat at the table.

Neuralink — one objective, radical execution.

Founded by Elon Musk in 2016, Neuralink's stated purpose is singular: build a working interface between human neurons and digital machines [2]. The technical term is Brain-Computer Interface. The practical application today: restoring communication and mobility to patients who lost both.

Five surgical implants. Verified digital control. FDA Investigational Device Exemption granted for human trials [2][3]. The science is real — and commercially immature by any standard used for quarterly results.

In 2025, Neuralink closed a $650M funding round, raising its valuation to approximately $9 billion [3]. That number signals conviction about the trajectory, not the quarter.

OIA — the logic of long-horizon capital.

The Oman Investment Authority manages a portfolio spanning 50+ countries across technology, infrastructure, healthcare, and energy [4]. Its structure divides across three strategic portfolios: the National Development Portfolio for domestic economy, the Generations Portfolio for long-term wealth, and the Oman Future Fund for far-horizon bets [4].

A Neuralink investment belongs naturally in the third category. The company will not generate Oman-relevant revenue next year. But investors who enter private rounds in frontier technology sit on advisory structures that shape industry standards — not just on shareholder lists.

The sovereign fund that waits for the IPO arrives at the table late. The one that enters in the private round buys part of the narrative, not only part of the cap table.

xAI first, Neuralink next.

In December 2024, OIA became among the first Gulf sovereign funds to announce a stake in xAI — Musk's AI company behind the Grok models [5]. At the time, some read it as a personality bet on Musk rather than a technology bet. The following months showed xAI building serious competition in the frontier model market.

Today, OIA adds Neuralink. The accumulation is intentional: not random diversification, but a deliberate position across one technology ecosystem that now spans consumer AI, frontier reasoning models, and direct brain interfaces.

What this means for Oman.

Oman Vision 2040 calls for economic diversification and a genuine position in the digital economy [6]. Direct investment in frontier technology companies is the financial translation of that intent. But the significance extends past financial returns.

• Governance presence: funds that enter early sit on advisory committees that write the standards for what is acceptable in this technology — globally.
• Knowledge transfer: early investment opens a formal channel for technical knowledge and capability-building that does not exist for passive observers.
• Healthcare alignment: Oman's Vision 2040 includes a healthcare advancement agenda. Partnering with pioneers in medical-adjacent technology draws a line between financial investment and national health strategy.

Honest limitations.

Neuralink faces a dual challenge: regulatory and technical. FDA clearance was granted for limited trials [2] — the path from clinical trials to broad deployment is long, expensive, and measured in decades rather than product cycles.

The company also faces unanswered questions on neural privacy: who owns the data pattern of your brain activity? How is it protected from commercial exploitation? Most regulatory frameworks globally have not yet answered these questions [3]. From OIA's perspective, the risk profile is appropriate for a sovereign portfolio planning on a twenty-year horizon. From a public accountability perspective, the expectation — expected return, expected timeline, expected Oman-specific benefit — deserves a clear public articulation.

At Nuqta, we see early sovereign capital in frontier biotech as a category of its own: part financial, part diplomatic, part industrial policy. The financial return may take fifteen years. The other returns begin accruing now.

The signal.

$650M raised in one round. $9B valuation for a company that does not yet sell a consumer product. Five patients who carry its chip — and a world watching what their once-still fingers now say.

OIA decided to be among those watching from the inside, not the outside. That is not purely a financial decision. It is a position: Oman does not intend to read in headlines about the biotech revolution a decade from now — it intends to be part of writing it today.

At Nuqta, we track Oman's sovereign technology investments and translate them for clients who want the full picture, not announcements in isolation. If you are building strategy in this space, we want to know what you are building.

Frequently asked questions.

• What is the Oman Investment Authority? OIA is Oman's sovereign wealth fund, managing the Sultanate's investment assets across three strategic portfolios and active in more than 50 countries worldwide [4].
• What does Neuralink do and how far along is it? It develops direct brain-computer interfaces. Its "Telepathy" device has been surgically implanted in five quadriplegic patients, enabling cursor control through thought alone. Current valuation: approximately $9 billion [2][3].
• Why invest in a company with no near-term profitability? Sovereign funds operate on 20–30 year horizons. Early-stage entry into frontier biotech provides governance seats and industry standard-setting influence, not only a financial position [4].
• Has OIA invested in Musk's companies before? Yes. In December 2024, OIA announced a stake in xAI, Musk's AI company. Neuralink is the second disclosed investment in the Musk technology ecosystem [5].
• What are the main risks? Regulatory risk — FDA pathway from trials to broad use is long — technical risk, and the absence of clear legal frameworks for neural data privacy in most jurisdictions [2][3].

Sources.

[1] Oman Investment Authority — Neuralink investment announcement, May 2026. (Official press release, 6 May 2026)

[2] Neuralink — Human Trials: PRIME Study.

[3] Reuters — "Neuralink raises $650 million, valuing brain-chip startup at about $9 billion" — Reuters, 2025.

[4] Oman Investment Authority — portfolio overview.

[5] Reuters — "Oman sovereign wealth fund OIA takes stake in Musk's xAI" — Reuters, December 2024.

[6] Oman Vision 2040 — National programme overview.